Providers

Pharmacists play a role in advising patients with hair loss about self-management and proper application of over the counter products.

Some of these symptoms include breast puckering, nipple discharge, and retracted nipple.

This new research sheds light on the importance of follow-up meetings for young patients discharged from emergency departments (EDs).

Mark A. Socinski, MD, discussed how the understanding of lung cancer has evolved over time, as well as how its heterogeneity impacts treatment strategies.

This qualitative study elucidates therapists’ perspectives on barriers to and facilitators of access to telemental health among Medicaid-enrolled youth served by a large safety-net organization.

In a recent review, researchers overviewed the challenging aspects of treating pulmonary arterial hypertension (PAH), highlight the genetic and etiological variability, and advocate for research to expand personalized medicine.

Residents grew more knowledgeable and more comfortable with using pre-exposure prophylaxis (PrEP) drugs for prevention against HIV after training was included in their residency program.

Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.

Understanding the needs of gender-diverse patients and patients receiving gender-affirming hormones is crucial to equitable care and properly addressing patients' needs.

This retrospective review compared appendicular lean mass (ALM) and ALM index among patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD).

HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others.

A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with improved outcomes.

Tirzepatide is already approved to treat type 2 diabetes, and is now approved for chronic weight management in adults with obesity or overweight with at least 1 weight-related condition.

Care in the fourth-trimester, when the birth has taken place and the mother and baby return home, is crucial for the well-being of the mother or the birthing person, Takiyah Durham, MBA, explains in an interview.

Three new novel treatments have shown promise in the treatment of multiple sclerosis (MS), including the potential to target neuroinflammation at its source.

When patients are undergoing treatment for cancer, clinicians should be aware of the potential to develop myasthenia gravis from immune checkpoint inhibitors (ICI), new research stresses, with ongoing surveillance and risk factor identification becoming necessary steps.

Rhenium (186Re) obisbemeda (Plus Therapeutics) shows potential to address the unmet need of new treatment options for patients with breast cancer and leptomeningeal metastases and will continue to be evaluated in the ReSPECT-LM program. The orphan drug designation (ODD) was granted on November 3.

Phathom Pharmaceuticals' vonoprazan (Voquenza) sets a new standard in erosive gastroesophageal reflux disease (GERD) therapy.

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant consideration of pharmacotherapy, and 1 in 48 had high levels of LDL-C that are indicated for medication.

Presenters at American Society of Nephrology Kidney Week 2023 highlighted the importance of understanding the barriers faced by the LGBTQ+ community that impact kidney outcomes and the need to gather better data for studying these issues.

There is great value, both for clinical trials and clinical practice, in biomarkers that identify patients at greatest risk of developing chronic kidney disease (CKD) after acute kidney injury, explained Steven Coca, DO, MS, Icahn School of Medicine at Mount Sinai.

Presenters at the American Society of Nephrology (ASN) Kidney Week 2023 highlighted the exciting new technologies that nephrology research has developed to improve patient outcomes, quality of life, and approaches to care.

This newly developed prediction model evaluating community-acquired pneumonia risk was noted to demonstrate accuracy, strong discriminatory qualities, and practicability in clinical settings.

Posters at ASN Kidney Week 2023 explored the economic burden brought on by chronic kidney disease (CKD) and further validated the Klinrisk model’s ability to predict progressive forms of CKD.

The Enhancing Oncology Model is trying to address a number of the systemic challenges oncology faces without giving practices the tools and resources they need, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.